First human test for Next-Gen flu shot begins
NCT ID NCT07349017
Summary
This is an early-stage study to check if a new flu vaccine, which includes a special ingredient called BK-01 adjuvant, is safe and can trigger a good immune response in healthy adults. Researchers will give the vaccine to 160 people and closely monitor them for any side effects for 30 days. The main goal is to see how safe the vaccine is and if people's bodies produce protective antibodies against the flu.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.